Enerceutical mediated activation of the Alternative Cellular Energy (ACE) pathway in the therapy of diseases

ABSTRACT

Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; or other activating components, such as magnesium chloride; with the combined mixture being put into a UV transparent container, such as a plastic bag, or placed on some other material, which can be laid onto the skin and illuminated with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients&#39; skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases including illnesses attributed to infections with stealth adapted and conventional viruses and diseases attributed to an inadequacy of the mitochondria and associated metabolic pathways, including states of hypoxia and nutritional deficiencies.

CROSS REFERENCE TO RELATED APPLICATIONS Co-Pending Patent ApplicationMethods for Detection of Ultraviolet Light Reactive Alternative CellularEnergy Pigments (ACE-pigments) William John Martin Submitted Dec. 24,2007 Method of Activating the Alternative Cellular Energy (ACE) Pathwayin the Therapy of Herpes Virus Infections William John Martin and SheilaCalderon Submitted Dec. 26, 2007

Method of Assessing and of Activating the Alternative Cellular Energy(ACE) Pathway in the Therapy of Diseases. William John Martin SubmittedJan. 17, 2008

Previously Submitted but Now Abandoned Patent Applications

Ser. No. 10/044,683. Therapy of stealth virus associated cancers andother conditions using light. William John Martin. (Abandoned)Ser. No. 10/047,313. Therapy of stealth virus associated cancers andother conditions using medium chain triglycerides. William John Martin.(Abandoned)Ser. No. 10/050,232. Diagnosing and monitoring the therapy of stealthvirus infections based on the detection of auto-fluorescent material inhair. William John Martin. (Abandoned)Ser. No. 10/058,480. Therapy of stealth virus associated cancers andother conditions using magnetic energy. William John Martin. (Abandoned)Ser. No. 10/164,258 Energy supportive therapy of stealth virusassociated diseases. William John Martin. (Abandoned)Ser. No. 10/174,466 Sound therapy of stealth virus associated diseases.William John Martin. (Abandoned)Ser. No. 10/192,936 ACE-Pigments and humic acids as energy sources.William John Martin. (Abandoned)

Submitted: 10/______ Methods for Collection of Alternative CellularEnergy Pigments (ACE-pigments). William John Martin. (Abandoned)

Submitted: 10/______ Methods for Elimination of Toxic AlternativeCellular Energy Pigments (ACE-pigments) and for Their Replacement UsingActivated Humates, including Humic and Fulvic Acids. William JohnMartin. (Abandoned)

United States Patents (Awarded)

U.S. Pat. No. 5,985,546 Stealth virus detection in the chronic fatiguesyndrome. William John MartinU.S. Pat. No. 5,891,468 Stealth virus detection in the chronic fatiguesyndrome. William John MartinU.S. Pat. No. 5,753,488 Isolated stealth viruses and related vaccines.William John MartinU.S. Pat. No. 5,703,221 Stealth virus nucleic acids and related methods.William John Martin

PCT (Patent Cooperation Treaty)

WO 92/20797 Stealth virus detection in the chronic fatigue syndrome.William John MartinWO 99/34019 Stealth virus nucleic acids and related methods. WilliamJohn MartinWO 99/60101 Stealth viruses and related vaccines. William John Martin

REFERENCES TO PUBLISHED ARTICLES Alternative Cellular Energy Pigments(ACE-Pigments):

-   1 Martin W J. Alternative cellular energy pigments mistaken for    parasitic skin infestations. Exp. Mol. Path 78: 212-214, 2005.-   2 Martin W J. Alternative cellular energy pigments from bacteria of    stealth virus infected individuals. Exp. Mol. Path 78: 217-217,    2005.-   3 Martin W J. Progressive Medicine. Exp Mol Path 78: 218-220, 2005.-   4 Martin W J, Stoneburner J. Symptomatic relief of herpetic skin    lesions utilizing an energy based approach to healing. Exp. Mol.    Path 78: 131-4, 2005.-   5 Martin W J. Etheric Biology. Exp Mol Path 78: 221-227, 2005.-   6 Martin W J. Stealth Virus Culture Pigments: A Potential Source of    Cellular Energy. Exp. Mol. Pathol. 74: 210-223, 2003.-   7 Martin W J. Complex intracellular inclusions in the brain of a    child with a stealth virus encephalopathy. Exp. Mol. Pathol. 74:    179-209, 2003.-   8 Martin W J. Photons and phonons: Theoretical aspects of biophysics    and potential therapeutic applications. Proceeding of Neural Therapy    Workshop on Sound and Light Therapy, Seattle, Wash., Feb. 21-23,    2003.

Stealth Adapted Viruses

-   1 Martin W J Chronic fatigue syndrome among physicians. A potential    result of occupational exposure to stealth viruses. Explore 2001;    10: 7-10.-   2 Martin W J. Stealth Viruses. Explore 2001; 10: 17-19.-   3 Durie G M, Collins R. Martin W J. Positive stealth virus cultures    in multiple myeloma. A possible explanation for neuropsychiatric    co-morbidity. Presented at the Am. Soc. Hematology annual meeting    October 2000.-   4 Martin W J. Chemokine receptor-related genetic sequences in an    African green monkey simian cytomegalovirus-derived stealth virus.    Exp Mol Pathol. 2000; 69:10-6.-   5 Martin W J., Anderson D. Stealth virus epidemic in the Mohave    Valley: severe vacuolating encephalopathy in a child presenting with    a behavioral disorder. Exp Mol Pathol. 1999; 66:19-30.-   6 Martin W J. Melanoma growth stimulatory activity (MGSA/GRO-alpha)    chemokine genes incorporated into an African green monkey simian    cytomegalovirus-derived stealth virus. Exp Mol Pathol. 1999;    66:15-8.-   7 Martin W J. Bacteria-related sequences in a simian    cytomegalovirus-derived stealth virus culture. Exp Mol Pathol. 1999;    66:8-14.-   8 Martin W J. Stealth adaptation of an African green monkey simian    cytomegalovirus. Exp Mol Pathol. 1999; 66:3-7.-   9 Martin W J. Cellular sequences in stealth viruses. Pathobiology    1998; 66:53-8.-   10 Martin W J. Detection of RNA sequences in cultures of a stealth    virus isolated from the cerebrospinal fluid of a health care worker    with chronic fatigue syndrome. Case report. Pathobiology. 1997;    65:57-60.-   11 Martin W J., Anderson D. Stealth virus epidemic in the Mohave    Valley. I. Initial report of virus isolation. Pathobiology. 1997;    65:51-6.-   12 Martin W J. Simian cytomegalovirus-related stealth virus isolated    from the cerebrospinal fluid of a patient with bipolar psychosis and    acute encephalopathy. Pathobiology. 1996; 64:64-6.-   13 Martin W J. Stealth viral encephalopathy: report of a fatal case    complicated by cerebral vasculitis. Pathobiology. 1996; 64:59-63.-   14 Martin W J. Genetic instability and fragmentation of a stealth    viral genome. Pathobiology. 1996; 64:9-17.-   15 Martin W J. Severe stealth virus encephalopathy following    chronic-fatigue-syndrome-like illness: clinical and    histopathological features. Pathobiology. 1996; 64:1-8.-   16 Martin W J. Stealth virus isolated from an autistic child. J    Autism Dev Disord. 1995; 25:223-4.-   17 Gollard R P, Mayr A., Rice D A, Martin W J. Herpesvirus-related    sequences in salivary gland tumors. J Exp Clin Cancer Res., 1996;    15: 1-4.-   18 Martin W J., Glass R T. Acute encephalopathy induced in cats with    a stealth virus isolated from a patient with chronic fatigue    syndrome. Pathobiology. 1995; 63:115-8.-   19 Martin W J, et al. African green monkey origin of the atypical    cytopathic ‘stealth virus’ isolated from a patient with chronic    fatigue syndrome. Clin Diag Virol 1995: 4: 93-103.-   20 Martin W J. Stealth viruses as neuropathogens. CAP Today. 1994;    8: 67-70.-   21 Martin W J. et al. Cytomegalovirus-related sequence in an    atypical cytopathic virus repeatedly isolated from a patient with    chronic fatigue syndrome. Am J. Pathol. 1994; 145: 440-51.-   22 Martin W J. Activation of the alternative cellular energy (ACE)    pathway as natural therapy for patients with autism. Submitted Mar.    27, 2008 to J. Autism and Developmental Disorders.-   23. Martin W J. Activation of the alternative cellular energy (ACE)    pathway as natural therapy for herpes simplex and herpes zoster    virus infections. Submitted Mar. 27, 2008 to J. Infectious Diseases    and subsequently to J. Complimentary and Alternative Medicine.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable: No Federal finding was received in support of thispatent application.

REFERENCE TO SEQUENCE LISTING, A TABLE OR A COMPUTER PROGRAM LISTINGCOMPACT DISK APPENDIX

Not applicable.

BACKGROUND OF THE INVENTION

The invention is based on the following broad conceptual understandingon how the body can acquire cellular energy other than through theoxidative metabolism of foods. Essentially, an alternative cellularenergy (ACE) pathway has been identified that is mediated by the energyconverting (transducing) properties of mineral containing complexes oforganic molecules, arbitrarily termed alternative cellular energypigments (ACE pigments) when derived from patients. Cellular energygenerated by this pathway can seemingly complement the chemical energythat is derived by living organisms from the metabolism of food. The ACEpathway is likely to contribute to various physiological functions ofthe body. Of particular relevance to this application, the ACE pathwayis postulated to provide an auxiliary defense mechanism beyond that ofthe immunological system, such that an inadequacy of this pathway maylimit the body's capacity to overcome various infectious diseases. TheACE pathway is also anticipated to be involved in the normal functioningof many organs, including the brain. Moreover, it is reasonable topresume that many illnesses, not necessarily of infectious origin, mayplace an added burden on the ACE pathway and that an inadequacy,deprivation or excessive demands on the ACE pathway may be a factor indelaying the normal disease recovery process. Conversely, augmenting oractivation of an impaired ACE pathway may facilitate recovery from awide range of various illnesses. Moreover, a fully functioning ACEpathway is likely to also be a factor in disease prevention, maintainingoptimal wellness, enhancing athletic performance, increasing cognitiveabilities, etc.

ACE pigments are envisioned as tiny batteries that can be either fullycharged or not fully charged with energy. In the latter state, ACEpigments can accept additional energy from various sources, includingultraviolet (UV) light. Absorption of UV light energy can be observed asthe emission of visible light; a process known as fluorescence. In somepatients, including patients in whom particles of ACE pigments aremisdiagnosed as parasites (delusional parasitosis or Morgellon'sdisease) direct fluorescence of ACE pigments can be readily observed. Inmany patients, however, the absorption of UV light energy and theresulting fluorescence by inadequately charged ACE pigments can bestrongly enhanced in the presence of certain dyes, including neutralred. ACE pigments can also interact with various other dyes, includingthe fluorescent dye acridine orange, yielding a multiplicity of colorsthat are well beyond the narrow spectrum of green light emitted solelyby UV illuminated acridine orange. Once a fluorescence reaction isevoked, nearby ACE pigments and other chemicals, without any directcontact with the dye, will also commonly undergo reactions thatpresumably reflect a physical energy transfer mechanism.

The potential linking and/or association between chemical reactions andeither the input or the emission of physical energies has not been asextensively studied as have the independent disciplines of biochemistryand biophysics. Photosynthesis provides a model system for theconversion of the energy contained within visible sunlight into chemicalbonding energy stored within carbohydrates. Other forms ofelectromagnetic radiation can be shown to facilitate various other typesof chemical reactions. It follows, therefore, that electromagnetic orother forms of energy emissions from a chemical reaction, or from energytransduction (conversion) by chemicals, can potentially have chemical orenergizing effects on reactants that are physically separated from theenergy source. Along with my studies, I have not uncommonly observedunusual behavior of unicellular microbes when in the vicinity, butwithout actual physical contact, with a chemical reaction. I have alsoobserved that fine particles in a neutral red solution will unexpectedlyundergo marked movements when placed near UV illuminated mineral richLidocaine (xylocaine) containing herbal solutions that are renderedfluorescent with neutral red and other dyes. More impressively, thedistinctive multi-point crystallization pattern of the neutral red thatcan be seen occurring in some of these solutions will also occur in adilute solution of neutral red that is simply held in close proximity toa fluorescing solution. Such a reaction is not seen when neutral redsolutions are simply exposed to UV light.

This indirect energy emitting process, triggered by a neutral red dyetriggered reaction with body-derived materials termed ACE pigments, hasbeen successfully used in expediting the healing of active skin lesionscaused by herpes simplex virus (HSV) and herpes zoster virus (HZV)infections. One can either use ACE pigments collected from the activelesions of the patients or a suitable formulated equivalent of ACEpigments as the source of emitted energy. ACE pigments can commonly beretrieved from the skin of patients with a history of recurrent herpesvirus lesions, as well as other diseases, and can be induced tofluoresce using neutral red. Patient derived ACE pigments or preferablya suitable formulated equivalent of ACE pigments have now beensuccessfully used in preventing future outbreaks in patients with aprior history of recurrent herpes who were treated during a period whenno active lesion was present.

As noted above patients with various other illnesses will commonlydisplay ACE pigments in skin and body secretions that will fluoresceunder UV light illumination in the presence of freshly prepared solutionof neutral red dye. Some of these additional illnesses have beenattributed to infections by stealth adapted viruses that fail to provokean anti-viral cellular immune response. Major categories of theseillnesses include the chronic fatigue syndrome, fibromyalgia,psychiatric and both acute and chronic neurological illnesses, autismand both behavioral and learning disorders in children, some cases ofcancer and many cases of general debilitating illness. Another groupingof illnesses includes patients in whom the mitochondria and associatedmetabolic energy pathways are deficient, because of hypoxia (as inemphysema), nutritional deficiencies, metabolic poisoning or geneticabnormalities. An assessment of the ACE pathway can be made bydetermining whether material that fluoresces upon the addition ofneutral red can be obtained from skin, saliva, urine, or other bodilyfluids or tissues of the patients. Such observations have led to thedevelopment of simple methods to assess a patient's ACE pathway and toprovide a clinical indication for efforts to recharge this pathway.These methods include the application of neutral red, either directly tothe patient's skin or onto an absorbent cloth on which ACE pigments werecollected from the patient by simply rubbing the cloth onto skin areas.Using this approach it was noted that many substances exist in Naturethat will fluoresce if mixed with neutral red and illuminated with a UVlight. It appears that the ACE pathway is a fundamental process inNature and conceivably a forerunner to more selective processes such asphotosynthesis. Organically complexed minerals, such as magnesium withinchlorophyll, are presumed to be critical elements in the capture andprocessing of external physical energies.

This concept is fully consistent with the finding that various mineraland organic substances can be formulated that similarly showfluorescence when mixed with neutral red and illuminated with UV light.Not all cellular energy delivering products show this reaction but mayyet presumably still be are able to absorb energies; and further thatsuch absorption may be facilitated using various types of dyes or otherchemicals. The advantage of a current formulation that has been devisedover the last several years is that it clearly fluoresces with neutralred and that a distant action can be easily observed in a distantly heldneutral red indication solution. This action includes otherwiseunexplained movements of fine particles within the neutral red solutionand more strikingly the induced crystallization that occurs in theneutral red solution. The present formulation has replaced the need forcollecting ACE pigments from the patient. It is also suitable as aliquid medium that when triggered to fluoresce with neutral red can becontained within a UV transparent plastic bag that can be placed ontothe skin of the patient and illuminated using a UV light source. Again,this method allows for the avoidance of direct contact of thetherapeutic solution with the patient's skin. The UV induciblefluorescence, or other form of energy emission, within the plastic bagswill typically evoke some discernable fluorescence within at least someskin areas in most of the treated and symptomatic patients, consistentwith an overall systemic activation of the body's ACE pathway. Suchactivation is taken as an indication that the ACE pathway in the patientis not fully charged and that the patient is likely to benefit fromfurther activation of the pathway. The liquid-in-a-bag format alsoallows for the addition of other materials that can further enhance theactivation and/or fluorescence of the formulations being studied.Materials under evaluation include iodine, magnesium chloride,hydrogen-rich water and others chemicals. Additional backgroundinformation is provided in the cited references of the inventor andthese publications are included by reference herein.

BRIEF SUMMARY OF THE INVENTION

The invention describes a method to treat a wide variety of illnesses aswell as potentially enhance the overall vitality and wellbeing ofindividuals. Specifically, the specification describes a method ofenergy-based activation of an alternative cellular energy (ACE) pathwayin humans as well as potentially in animals. This pathway is mediated byenergy transducing materials termed alternative cellular energy pigments(ACE pigments). In some individuals, both as a cause and a consequenceof disease, the ACE pigments are not sufficiently activated (orcharged). This lack of full activation or charging can be inferred ifpatient derived ACE pigments can be shown to fluoresce under UV lightillumination when contacted with freshly prepared neutral red dye. Thelack of detectable fluorescing material from the skin, buccal swabs(saliva) or urine is, conversely, presumptive evidence that at least oneaspect of the ACE pathway is either fully charged or not being calledupon to the extent it is in patients in whom fluorescence material canbe collected. Patients have been identified in whom skin-derived,neutral red inducible-UV fluorescing material was present even though atthe time there was no actual skin disease observed. Neutral redinducible and occasionally unaided UV fluorescence has also been shownin hair samples and in buccal swabs obtained from patients with avariety of systemic illnesses. Skin derived ACE pigments have beencollected onto Q-tips and onto absorbent gauze swabs and surgicaldressings. The materials used to collect the ACE pigments were stainedwith neutral red and placed over the skin areas from which the materialwas collected, avoiding direct contact of the dye with the skin with forexample an intervening Saran Wrap or plastic coated toweling. The Q-tipor other material used to collect the ACE pigments fluoresced whenilluminated with UV light. Furthermore, the fluorescence on the Q-tip orother material appeared to activate a fluoresce reaction that involvedthe patient's skin. The fluorescence in the patient's skin graduallysubsided over a 10-60 minute period. Of the various patients so treated,they have consistently reported improvements in their sense ofwellbeing. This approach provided a useful method to seemingly “jumpstarting” the ACE pathway.

Various natural products possess ACE pigment like activities and havebeen termed “enerceuticals” by the inventor. They are defined asmaterials that are capable of transducing (converting) physical energiesinto an energy form that can be utilized by living cells as analternative to chemical energy derived from the metabolism of nutrientsand which have the following distinguishing characteristics: i) Canprovide therapeutic benefits as well as a general vitality enhancingeffects to plants, animals and humans; ii) their potential therapeuticeffects are not limited or restricted to any particular type or groupingof illnesses; and iii) that do not need to specifically localize to thedisease tissues since they can generate field effects that extend beyondtheir physical location. These criteria distinguish enerceuticals fromboth pharmaceuticals and nutraceuticals.

An example of an enerceutical is a terpine/terpenoid rich mixture ofsteam-extracted sap from Japanese cedar, cypress and pine trees andplantain plants. It is marketed as HB-101 for agricultural use and asEH-101 when used as a dietary supplement in humans. This product wassimply regarded as a nutrient until the inventor drew attention to itsremarkable property of still being active at 1:10,000 dilutions,delaying the spoiling of caught whole fish even when simply included inthe ice used to pack the intact fish, and interacting in vigorous energyexchange reactions with tincture of iodine, leading to products that canhave distant effects on microbes. Another enerceutical product wasformulated from xylocaine (Lidocaine) by the addition of sodium chloridedepleted mineral salts obtained from the Great Salt Lake in Utah andmarketed by Marine Minerals, Inc. Electrostatically active,needle-shaped crystals form that can both directly and after interactionwith tincture of iodine, affect the behavior of microbes placed in aseparate water droplet on the same microscope slide as the crystals.Various additional minerals and herbal products, suggested by a reviewof stated components of other energy delivering commercial andinvestigative products, have been included in variously modifiedformulation of Lidocaine-containing enerceuticals. One such product hasbeen provisionally designated Epione. The herbal components weresuggested from data pertaining to two related products, one known asCarnova and the other as HANSI (now also known as Enercel). Neither ofthese products will fluoresce with neutral red. The Epione formulationgives a bright UV light induced orange fluorescence when mixed withfreshly prepared neutral red. Lidocaine by itself will not fluorescewhen mixed with neutral red. Nor will this enerceutical when it istested without contact with neutral red. UV illumination of the neutralred stained enerceutical preparation will induce small multi-pointedcrystallization and heightened movement within a dilute neutral redsolution physically separated from the fluorescing solution. This methodhas provided a simple assay to confirm the apparent physical energytransfer from the activated enerceutical preparation.

The present invention relates to combining this particular or equivalentenerceutical with neutral red to create a UV fluorescing solution thatcan be placed into a plastic bag or soaked into an absorbent cloth thatis simply laid onto the skin and illuminated with a UV light source, soas to activate the ACE pathway in an ACE pathway deprived human oranimal. The activation process can be achieved over a time periodranging from several minutes to over an hour. The size of the plasticbagging can also vary widely; the largest being tried is 17″×11″. Asmaller size is more appropriate for treating a localized lesion. The UVlight source is typically one or more light bulbs or various strengthsand sizes and includes the 13 watt spiral UV light that is mostconvenient for localized lesions.

BRIEF DESCRIPTION OF THE DRAWINGS

Not Applicable and none included

DETAILED DESCRIPTION OF THE INVENTION

Rather than relying upon neutral red to interact directly with ACEpigments derived from a patient, I have discovered that an enerceuticalproduct can be used with neutral red to help initiate the activation ofthe body's own ACE pigments. It is also likely that the enerceuticalproduct can function directly by itself or with various other dyes. In apreferred embodiment, however, neutral red is used to activate adiscernable fluorescence within the enerceutical formulation. In atypical example, up to hundred milliliters of the selected enerceuticalsolution is vigorously shaken and poured into a plastic bag to providefluid coverage over a skin surface of a patient. The bag is placed onthe patient's skin. The enerceutical solution is held under UVillumination just prior to the addition of a neutral red solution in asufficient amount to achieve marked fluorescence. The actualconcentration and amount of neutral red solution used can be variablebut typically is about 1 mg/ml and at about a tenth of the volume of theenerceutical product. The intent is to only use sufficient neutral redto achieve maximum UV-A induced fluorescence. After gentle mixing, theUV illumination is continued for approximately an hour with a UV lightcomprising either fluorescent tubes or spiral light bulbs thatselectively emit UV-A light. If the patient has an existing skin lesionor a prior history of recurrent skin eruptions, the bag will be placedover the involved areas of skin. Preference is also given to areas whereperspiration tends to accumulate (groin areas, axilla and scalp) nerveinnervations tend to be concentrated (face, hands and feet) or over thespine. Several illuminated bags can be used in the one patient ifdesired and the patient can be placed inside a chamber fitted with UV-Alights. UV illumination generally continues for approximately an hour.Incidentally, the palate will also commonly show UV induciblefluorescence during the procedure with subsequent fading. A smallseparate container of neutral red by itself can also be placed near thefluorescing bag and subsequently examined for crystallization of theneutral red solution as a marker of energy transfer from the fluorescingsolution.

A suitable enerceutical is the xylocaine-mineral-herbal formulation,tentatively called Epione. It comprises 0.1% xylocaine together withcalcium chloride, potassium chloride, magnesium chloride and magnesiumsulfate as minerals in an aqueous solution containing 5% ethyl alcohol.Homeopathic quantities of a solution containing the herbal productsAconite napellus, Bryonia alba, Chelidonium, Cinamium, Pulsatilla,Lachesis and Thuja, are also included. Of the various components, thecalcium, potassium, magnesium and xylocaine are considered as formingthe major energy transducing complexes. Fluorescence reactions withinthe particular enerceutical formulation can also be achieved using thealready fluorescent dye acridine orange.

Additional approaches under consideration include the further additionof saturated magnesium chloride in the range of 10% of the amount ofenerceutical used. The magnesium chloride forms numerous fine particlesthat undergo progressive waves or burst of movements somewhat similar tothe vigorous reactions seen with tincture of iodine added to theenerceutical. The reactions become less intense over a period of severalminutes. Magnesium flakes have also been added as a means of generatinghydrogen within the enerceutical-magnesium chloride mixture.Furthermore, rather than chemical grade magnesium chloride, I have alsoused the marine mineral sodium chloride depleted water from the GreatSalt Lake. The major residual component is magnesium chloride.

Various volunteers have been treated using the fluid-in-a-bag protocol.Subjective determination is that the method provides more energy thandoes the use of fluorescing towels. Improvements have been noted in thetime one can hold one's breadth validating earlier findings of benefitsin patients with emphysema. The bags progressively lose activity afterthe 1-2 hour time period presumably as a result of the observedpolymerization of neutral red into fine multi-spiked crystals. It isanticipated that further refinements of the protocol will be made asclinical studies continue. One such refinement is to substitute sunlightas the source of UV illumination.

The described approach is suitable for self-administration and certainlyfor a parent to administer to a child, including a child with autism,ADHD, etc. In conformity with FDA regulations various participants canbe qualified as their own clinical investigator or this relativelysimple procedure.

The principles, preferred embodiments and modes of operation of thepresent invention have been described in the foregoing specification.The invention which is intended to be protected herein, however, is notto be construed as limited to the particular enerceutical or dyedisclosed, since they are to be regarded as illustrative rather thanrestrictive. Nor is the invention intended to be necessarily restrictedto UV light as the source of physical energy. In some protocols,exposure to sunlight may suffice. Moreover, it is likely that portionsof the electromagnetic spectrum other than UV light will prove to beuseful with enerceuticals, with or without the inclusion of a dye, foractivation of the ACE pathway in an ACE energy-deprived subject. Nor isthe invention dependent upon the precise decision as to what does ordoes not constitute an enerceutical. Basically, the claims relate to thebroader issue of achieving therapeutic benefit through activation of theACE pathway with the description of the currently preferred andpracticed method. Additional advantages and modifications will readilyoccur to those skilled in the art and especially upon practicing thecurrently described methods. Variations and changes may be made withoutdeparting from the spirit of the invention encompassed by the appendedclaims.

1. A method for activating the alternative cellular energy (ACE) pathway in an ACE energy deprived human or animal subject comprising the ultraviolet (UV) light illumination of an enerceutical product, used either alone or mixed with a suitable dye, with the enerceutical product or mixture being first placed in a plastic or other UV light transparent container that is laid upon the skin surface, or is held in close proximity to the skin, and illuminated with UV light for the purpose of expediting the healing of a disease process affecting the subject.
 2. The method of claim 1 in which the enerceutical is a solution containing xylocaine, minerals and herbal extracts formulated in such a manner that it fluoresces under UV illumination when mixed with the dye at a concentration sufficient to achieve UV inducible fluorescence.
 3. The method of claim 1 in which the activity of the enerceutical solution is further enhanced by the addition of materials, that evoke a reaction within the enerceutical solution manifested by the formation of rapidly moving microscopically discernable particles that engage in a time limited flurry of vigorous interactions.
 4. The method of claim 2 in which the enerceutical product is rendered fluorescent by using a solution the dye neutral red at a concentration ranging from 0.05 to 5.0 mg/ml.
 5. The method of claim 2 in which the enerceutical product is rendered fluorescent by using a solution of acridine orange at a concentration ranging from 0.05 to 5.0 mg/ml.
 6. The method of claim 3 in which the added component is a solution containing magnesium chloride.
 7. The method of claim 3 in which the added component is tincture of iodine.
 8. The method of claim 1 in which the disease is caused by herpes simplex virus (HSV), herpes zoster virus (HZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpesviruses 6-8 (HHV6, HHV7 and HHV8).
 9. The method of claim 1 in which the disease is caused by human papillomaviruses
 10. The method of claim 1 in which the disease is caused by human immunodeficiency virus (HIV).
 11. The method of claim 1 in which the disease is caused by human hepatitis viruses.
 12. The method of claim 1 in which the diseases is presumptively caused by atypical (stealth adapted) viruses that lack antigenic components capable of activating an effective anti-viral cellular immune response
 13. The method of claim 1 in which the diseases is characterized by the formation on the skin and hair of alternative cellular energy (ACE) pigments having the form of particles and fibers and that has been referred to as Morgellon's disease
 14. The method of claim 1 in which the disease is autism or a related illness, including childhood learning and behavioral disorders.
 15. The method of claim 1 in which the disease is a psychiatric illness.
 16. The method of claim 1 in which the disease is the chronic fatigue syndrome or a related illness, including fibromyalgia and depression.
 17. The method of claim 1 in which the disease is caused by hypoxia as occurs in illnesses such as emphysema, or a metabolic or nutritional deficiency. 